Loading...
•
Dec 31, 2025
Teva Q4 2025 Earnings Report
Teva reported strong Q4 2025 results with significant revenue growth and a return to profitability.
Key Takeaways
Teva delivered solid Q4 2025 results driven by its innovative portfolio, especially AUSTEDO and AJOVY, alongside a major development milestone payment. The company returned to profitability, with revenue and net income increasing significantly year-over-year.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Teva expects modest top-line growth with continued strength in its innovative pipeline and strong profitability.
Positive Outlook
- Revenue guidance set at $16.4B to $16.8B
- Expected non-GAAP EPS of $2.57 to $2.77
- Free cash flow guidance of $2.0B to $2.4B
- Adjusted EBITDA projected between $5.0B and $5.3B
- Strong growth anticipated in AUSTEDO, AJOVY, and UZEDY
Challenges Ahead
- Expected revenue decline from 2025 actuals
- Foreign exchange volatility could impact revenue and income
- Generics and OTC pricing pressures continue
- Operational risks in transformation programs remain
- Uncertainties tied to regulatory approvals and late-stage pipeline
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...